Seven-year follow-up data show that transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement have ...

Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA. At ...

People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...

A troubling rise in severe diverticulitis cases among Americans under 50 highlights a significant public health concern.

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

In an October 27, 2025 precedential opinion, Aortic Innovations LLC v. Edwards Lifesciences Corp., No. 2024-1145, the Federal Circuit affirmed ...